OncoSec Medical Inc (ONCSQ)

[chickpea598]

Orphan drug designation will give Oncosec 7 years of exclusivity when they get accelerated approval next year. With an annual patient population of 3,000 patients at $150,000 for 7 years, just in the United States alone, that is a huge market opportunity. Just the prospects of that alone should have institutions hoarding into Oncosec stock with the recent data release.